Electronic Supplementary Material

Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-Small-Cell Lung Cancer (JO25567): Updated Safety Results

Target journal: Drug Safety

Terufumi Kato[1] · Takashi Seto[2] · Makoto Nishio[3] · Koichi Goto[4] · Noboru Yamamoto[5] · Isamu Okamoto[6] · Liang Tao[7] · Wei Yu[8] · Tarik Khaznadar[9] · Kosei Tajima[10] · Masahiko Shibata[10] · Akihiro Seki[10] · Nobuyuki Yamamoto[11]

[1]*Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Japan.*

[2]*National Kyushu Cancer Center, Fukuoka, Japan.*

[3]*The Cancer Institute Hospital of the Japanese Foundation for Cancer Research, Tokyo, Japan.*

[4]*National Cancer Center Hospital East, Chiba, Japan.*

[5]*National Cancer Center Hospital, Tokyo, Japan.*

[6]*Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.*

[7]*Roche (China) Holding Ltd, Building 11, 1100 Longdong Avenue, Shanghai 201203, China.*

[8]*Genentech Inc., 1 DNA Way, South San Francisco*, CA 94080, *USA.*

[9]*F. Hoffmann-La Roche Ltd*, *Grenzacherstrasse 124, Basel, CH-4070 Switzerland.*

[10]*Chugai Pharmaceutical Co. Ltd, Tokyo, Japan.*

[11]*Wakayama Medical University, Wakayama, Japan.*

Corresponding author:

Terufumi Kato, Department of Respiratory Medicine, Kanagawa Cancer Center, 2-3-2 Nakao, Asahi-ku, Yokohama, Kanagawa 241-8515, Yokohama, Japan.

Email: terufumikato@gmail.com

Supplementary Table S1. Criteria for interruption of administration, drug discontinuation, dose reduction, and discontinuation of administration of bevacizumab or erlotinib in JO25567

Adverse event		JO25567
Hypertension	Grade 3	Defer bevacizumab until controlled (use of anti-hypertensives possible).
	Grade 3	Continue erlotinib but can be withdrawn until recovery to grade ≤1 according to investigator judgement.
Proteinuria	Grade 2	If decreased albumin or edema is seen, defer administration until recovery to ≤grade 2. Continue if protein:urine ≤2g/24hr.
	Grade 3	Defer bevacizumab; restart if recovery to ≤grade 2 and decreased albumin or edema is not seen or protein:urine ≤2g/24hr.
	Grade 3	Withdraw erlotinib until ≤grade 2, then restart at the same dose; dose reduction is also possible.
Hemorrhage (excluding hemoptysis)	Grade 2	Defer until recovers to grade 0. If hemorrhage ≥grade 2 after a restart, discontinue bevacizumab.
	Grade 3	Discontinue bevacizumab.
	Grade 3	Erlotinib withdrawal until recovery to ≤grade 1.
Hemoptysis (including bloody sputum)	Grade 1 and Grade 2	Grade 1 and 2 that require treatment with an oral hemostatic; defer until grade 0.
	Grade 2 and Grade 3	Grade 2 and 3 that require treatment with an injectable hemostatic; discontinue bevacizumab.
	Grade 3	Erlotinib withdrawal until recovery to ≤grade 1.